Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06597734
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
- Conditions
- Interventions
- Biological: Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyDrug: CyclophosphamideDrug: DecitabineProcedure: EchocardiographyDrug: FludarabineProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT06572631
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06561074
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
- Conditions
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-11-29
- Target Recruit Count
- 37
- Registration Number
- NCT06511882
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
- Conditions
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06474663
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT06445959
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 152
- Registration Number
- NCT06441097
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-05-24
- Target Recruit Count
- 40
- Registration Number
- NCT06429098
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China
🇨🇳Ethical Committee of the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06401603
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT06383572
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.